CohBar’s treatment of idiopathic pulmonary fibrosis, or IPF, was granted orphan status by the FDA, according to a post to the agency’s website. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CWBR: